SynthesisBMC cancer2025
Comparing the biopsy strategies of prostate cancer: a systematic review and network meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Trial
- Article
- Transperineal cognitive versus trans-rectal fusion biopsy under local anesthesia: multicenter outcomes in detection rates, complications, and feasibility.International urology and nephrology · 2026Article
- Optimising the prostate cancer diagnostic pathway in a tertiary hospital in Karachi: a two-cycle quality improvement project.BMJ open quality · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of three kinds of magnetic resonance imaging-guided prostate biopsies (MRI-PB) has changed the paradigm regarding prostate biopsies (PB). We aimed to compare and rank PB strategies to provide the latest evidence of PB option for prostate cancer (PCa) diagnosis. We searched PubMed, the Cochrane Library Central, Scopus, Embase and the reference lists of relevant articles for randomized controlled trials published up to Dec, 2024, of different PB strategies. Finally, 24 randomized trials were included. Eleven PB strategies published were considered. For overall PCa detection rates exclusively previously negative biopsy patients, we found robust improvements of 3.92 (95% CI: 2.17-6.41) for MRI-cognitive- and 1.78 (95% CI: 1.02-3.07) for MRI/TRUS- compared to TRUS(10-12)-PB. For PCa detection when prostate volume ≤ 50 mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.